WO1993025211A1 - Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale - Google Patents
Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale Download PDFInfo
- Publication number
- WO1993025211A1 WO1993025211A1 PCT/US1993/005812 US9305812W WO9325211A1 WO 1993025211 A1 WO1993025211 A1 WO 1993025211A1 US 9305812 W US9305812 W US 9305812W WO 9325211 A1 WO9325211 A1 WO 9325211A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- itching
- stannous fluoride
- inflammation
- treatment
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Definitions
- the present invention relates to a treatment for the cutaneous pain, itching and inflammation often associated with allergies, burns, trauma, insect bites and bacterial, viral and fungal infections. More particularly, the invention relates to the topical application of stannous fluoride for the treatment of such symptoms.
- the present invention meets this object by providing a treatment which includes the topical application of stannous fluoride.
- a non-toxic amount of stannous fluoride is incorporated into a pharmaceutical carrier, such as a gel, ointment, cream, lotion or the like, and applied at the site of the inflammation, itching or lesion.
- the stannous fluoride is provided in a concentration ranging from about 0.1 wt. % to about 8 wt. %.
- the stannous fluoride is applied as a 0.4% SnF2 glycerin-based gel.
- the frequency of application may range anywhere from one to six times a day or on an as needed basis.
- the course of therapy typically ranges from one to ten days but may be continued as long as required for complete relief. DETAILED DESCRIPTION OF THE INVENTION
- a non-aqueous stannous fluoride gel is prepared by solubilizing SnF2 in glycerin at approximately 150°F for four hours.
- the resulting gel is a stable solution having an indefinite shelf life that is ideal for topical application to the skin and mucusal tissues.
- stannous fluoride promotes relief from pain, itching and inflammation; however, the mechanism by which the compound effects these results is not clearly understood.
- tin (Sn ++ ) and fluoride (F”) ions interact together and affect nerve action potentials, histamine release, cellular enzyme systems and vascular systems, all of which can influence the pain, itching and inflammation caused by infection, allergies and trauma.
- EXAMPLE 1 Two patients exhibiting an allergic reaction to poison ivy were instructed to apply 0.4% SnF2 gel 4 to 6 times a day or on an as needed basis. Relief from pain and itching was obtained almost immediately.
- EXAMPLE 2 Five patients with burns were instructed to apply 0.4% SnF2 gel 4 to 6 times a day or on an as needed basis. Relief from the pain associated with the bums was obtained almost immediately.
- EXAMPLE 3 Ten patients having insect bites (7 mosquitoes, 2 bees) received immediate relief from the associated pain, inflammation and itching when 0.4% SnF2 gel was applied. EXAMPLE 4
- EXAMPLE 5 Fifteen patients infected with herpes zoster virus and 30 patients infected with herpes simplex virus were instructed to apply 0.4% SnF2 gel 4 to 6 times a day. The pain and itching associated with the infections was either eliminated completely or significantly reduced.
- EXAMPLE 6 Eight patients having acne infections of bacterial origin on the skin obtained relief from the pain associated with the infections when 0.4% SnF2 gel was applied.
- EXAMPLE 7 Two patients infected with ringworm and eight patients infected with athletes foot were instructed to apply 0.4% SnF2 gel 4 to 6 times a day or on an as needed basis. Relief from the itching and pain associated with the infections was obtained almost immediately.
Abstract
L'invention concerne un traitement des douleurs cutanées, du prurit et d'inflammations associées à des allergies, des brûlures, des traumas, des piqûres d'insectes et des infections bactériennes, virales et fongiques. Selon l'invention, une dose non toxique de fluorure d'étain est incorporée dans un excipient pharmaceutique approprié et administrée localement.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU45388/93A AU4538893A (en) | 1992-06-16 | 1993-06-16 | Treatment for cutaneous pain, itching and inflammation with topical stannous fluoride |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89798892A | 1992-06-16 | 1992-06-16 | |
US07/897,988 | 1992-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993025211A1 true WO1993025211A1 (fr) | 1993-12-23 |
Family
ID=25408759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/005812 WO1993025211A1 (fr) | 1992-06-16 | 1993-06-16 | Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4538893A (fr) |
WO (1) | WO1993025211A1 (fr) |
ZA (1) | ZA934273B (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658946A (en) * | 1996-05-29 | 1997-08-19 | The Procter & Gamble Company | Methods for the treatment of herpes virus infections |
EP0801554A1 (fr) * | 1994-12-21 | 1997-10-22 | Cosmederm Technologies | Formulations et procedes pour diminuer l'irritation de la peau |
US5908640A (en) * | 1997-07-25 | 1999-06-01 | Embro; William J. | Veterinary compositions for treating epidermal irritations |
US6294186B1 (en) | 1997-06-04 | 2001-09-25 | Peter William Beerse | Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
US6436885B2 (en) | 2000-01-20 | 2002-08-20 | The Procter & Gamble Company | Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid |
US8147855B2 (en) | 1994-12-21 | 2012-04-03 | Cosmederm Bioscience, Inc. | Methods for inhibiting sensory responses in the skin such as pain and itch using topical product formulations containing strontium |
EP4014962A1 (fr) * | 2020-12-16 | 2022-06-22 | Novigo GmbH & Co. KG | Composition comprenant une substance à action osmotique et utilisation de la composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4563489A (en) * | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
US4639366A (en) * | 1984-06-06 | 1987-01-27 | Merck & Co., Inc. | Polymers containing pendant acid functionalities and labile backbone bonds |
US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
-
1993
- 1993-06-16 ZA ZA934273A patent/ZA934273B/xx unknown
- 1993-06-16 WO PCT/US1993/005812 patent/WO1993025211A1/fr active Application Filing
- 1993-06-16 AU AU45388/93A patent/AU4538893A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4563489A (en) * | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
US4639366A (en) * | 1984-06-06 | 1987-01-27 | Merck & Co., Inc. | Polymers containing pendant acid functionalities and labile backbone bonds |
US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455076B1 (en) | 1994-12-21 | 2002-09-24 | Gary S. Hahn | Formulations and methods for reducing skin irritation |
EP0801554A1 (fr) * | 1994-12-21 | 1997-10-22 | Cosmederm Technologies | Formulations et procedes pour diminuer l'irritation de la peau |
US8449923B2 (en) | 1994-12-21 | 2013-05-28 | Cosmederm Bioscience, Inc. | Methods for inhibiting sensory nerves by topically administering strontium-containing compositions to keratinized skin |
US8147855B2 (en) | 1994-12-21 | 2012-04-03 | Cosmederm Bioscience, Inc. | Methods for inhibiting sensory responses in the skin such as pain and itch using topical product formulations containing strontium |
EP0801554A4 (fr) * | 1994-12-21 | 2000-03-29 | Cosmederm Technologies | Formulations et procedes pour diminuer l'irritation de la peau |
US5747070A (en) * | 1996-05-29 | 1998-05-05 | The Procter & Gamble Company | Methods for the treatment of herpes virus infections |
US5744167A (en) * | 1996-05-29 | 1998-04-28 | The Procter & Gamble Company | Methods for the treatment of herpes virus infections |
US5658946A (en) * | 1996-05-29 | 1997-08-19 | The Procter & Gamble Company | Methods for the treatment of herpes virus infections |
GB2313543A (en) * | 1996-05-29 | 1997-12-03 | Procter & Gamble | Compositions containing stannous halides and/or stannous carboxylates for the treatment of herpes virus infections |
US6294186B1 (en) | 1997-06-04 | 2001-09-25 | Peter William Beerse | Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
US5908640A (en) * | 1997-07-25 | 1999-06-01 | Embro; William J. | Veterinary compositions for treating epidermal irritations |
US6436885B2 (en) | 2000-01-20 | 2002-08-20 | The Procter & Gamble Company | Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid |
EP4014962A1 (fr) * | 2020-12-16 | 2022-06-22 | Novigo GmbH & Co. KG | Composition comprenant une substance à action osmotique et utilisation de la composition |
WO2022129425A1 (fr) * | 2020-12-16 | 2022-06-23 | Novigo GmbH & Co. KG | Composition contenant une substance osmotique et utilisation de la composition |
Also Published As
Publication number | Publication date |
---|---|
ZA934273B (en) | 1994-08-01 |
AU4538893A (en) | 1994-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1085804B1 (fr) | Procede et composition pour le traitement d'irritations et d'infections epidermiques | |
US4708965A (en) | Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives | |
US4424232A (en) | Treatment of herpes simplex | |
Niwa | Lipid peroxides and superoxide dismutase (SOD) induction in skin inflammatory diseases, and treatment with SOD preparations | |
US20040131693A1 (en) | Composition with a base of a therapeutically active compound, in particular honey, for the treatment of wounds | |
EP0988040B1 (fr) | Utilisation de glucosamine et de derives de glucosamine pour le soulagement rapide de prurit ou de douleurs localisees | |
US5420114A (en) | Methods for the treatment of skin disorders | |
KR101099550B1 (ko) | 봉독을 유효성분으로 하는 상처 또는 화상 치료용 조성물 | |
WO1993025211A1 (fr) | Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale | |
US6352711B1 (en) | Lesion and ulcer medication | |
US5098716A (en) | Method and composition for treating diseases having a viral etiology | |
US6562326B1 (en) | Topical composition for burn healing | |
US5049580A (en) | Treatment of inflamed skin conditions including poison ivy and poison sumac, insect bites and acne | |
WO1992006700A1 (fr) | Preparation topique et procede de suppression d'eruptions cutanees provoquees par le virus de l'herpes simplex | |
US3751565A (en) | Therapeutic compositions | |
ATE152356T1 (de) | Topisches präparat zur besseren heilung von herpesverletzungen | |
US4466956A (en) | Method of therapy for oral herpes simplex | |
US3764669A (en) | Method of making microbiocidal complexes | |
US5151415A (en) | Method of treating a papova-type viral infection | |
US5977176A (en) | Compositions for the treatment of warts and herpes | |
US5576005A (en) | Effectiveness of wart removal by compositions including propolis | |
US20030092682A1 (en) | Use of doxycycline for treatment of certain skin and mouth ailments | |
US10905729B1 (en) | Formulations and methods for wound treatment | |
Rallos et al. | Wound contraction effect of Bermuda grass (Cynodon dactylon) topical cream on induced second-degree burn in male albino mice | |
DE3035069C1 (de) | Saures dermatologisches Praeparat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase | ||
122 | Ep: pct application non-entry in european phase |